Instructions for No-Spa Forte (Drotaverine) pills
Pharmaceutical properties:
Drotaverin is a spasmol, a derivative of isochinolin, acts directly on smooth muscles by inhibiting FDE type IV and intracellular accumulation of zAMF, which results in relaxation of smooth muscles by inactivating the mild chain of myoine .
In vitro dartaverin suppresses enzyme action of FDE IV and inhibiates isoferment of FDE III and FDE V. FTE IV has great functional value for reducing the contractionary activity of smooth muscles, so selective inhibitors of this enzyme can be effective for treating diseases associated with hypermobility, as well as various diseases during which there are spasms of LCD.
In the cells of smooth myocardial muscles and vascular cAMF hydrolyzed mainly by isofermentation of FDE III, therefore the dartaverine is an effective spasprama remedy, having no significant side effects from the cardiovascular system and a pronounced therapist of this system.
Drotaverine is effective in smooth musculature spasms of both nervous and muscle origin. Drotaverine acts on smooth musculature of gastrointestinal, biliar, urinary and vascular systems, regardless of their type of autonomous innervation.
The drug No-Spa increases blood circulation in the tissues because of its ability to expand the blood vessels.
The action of the dartaverine is more pronounced than the action of the papaverin, the absorption is faster and more complete, it is less associated with the proteins of the blood serum. The advantage of the Drotaverine is that, unlike papaverin, after its parenteral introduction, there is no side effect such as breathing stimulation.
Drotaverine is quickly and completely absorbed in both parenteral and oral applications. To a large extent (95-98%) is associated with blood plasma proteins, especially albumin, gamma- and beta-globulins. The maximum concentration is reached within 45-60 minutes after oral application. After the primary metabolism, 65% of the dose received goes into blood circulation in an unaltered form.
Metabolized in the liver. The half-time period is 8-10 h. In 72 h it is almost completely removed from the body, about 50% - with urine, 30% - with calum. Basically — in the form of metabolites, in the same form in the urine is not defined.
- Testimony:
- In order to treat adults with:
- spasms of smooth musculature associated with bile tract diseases: cholecystolytes, cholangiolithiasis, cholecystitis, pericholecystitis, challite, papylita;
- spasms of smooth musculature in diseases of the urinary tract: nephrolytiasis, ureterolyase, peliitis, cystitis, bladder tenesma.
- For the purpose of assistive therapy with:
- spasms of smooth musculature of the gastrointestinal tract: ulcers of the stomach and duodenum, gastritis, cardio and/or pylorospasm, enteritis, colitis, spastic colitis with constipation and irritable bowel syndrome, which is accompanied by flatulence;
- tension headache;
- gynaecological diseases (dysmenorrhea).
application:
Adults: the usual average dose is 120-240 mg per day for 2-3 doses. The duration of treatment is determined individually.
contraindications
Increased sensitivity to drotaverin or any component of the drug No-Spa. Severe hepatic, renal or heart failure (small cardiac ejection syndrome). Deficiency of lactase, galactosemia or malabsorbation syndrome of glucose-galactose. Breastfeeding period. Children's age.
Side effects:
Side-effects observed in clinical trials and caused by the intake of drotaverin are classified by organs and systems, as well as by the frequency of occurrence: very often (≥1/10), often (≥1/100, but ≤1/10), infrequently (≥1/1000, but ≤1/100), rarely (≥1/10,000, but ≤1/1000), very rarely (≤1/10,000), including isolated cases.
Violations from the gastrointestinal tract: rarely - nausea, constipation.
From the nervous system: rarely - headache, dizziness, insomnia.
From the cardiovascular system: rarely - tachycardia, arterial hypotension.
There are isolated reports of allergic reactions, including swelling of Kwinke.
Special Instructions:
Each pill of the No-Shpa Forte drug No-Spa contains 104 mg of lactose. If used according to the recommended doses, the body can receive up to 156 mg of lactose per 1 dose, which can cause complaints by LCD patients with lactose intolerability.
Do not use for treatment of patients with congenital lactase deficit, galactomethium or halactose glucose malabsorption syndrome.
Use during pregnancy and breastfeeding. As the results of retrospective clinical trials showed, oral application of the drug No-Spa did not cause teratogenic and embryotoxicine effect. However, it is necessary to administer the drug with care to women during pregnancy.D
ue to the lack of data from the relevant studies during breastfeeding, the use of the drug No-Spa is not recommended.
Kids. The use of a drug No-Spa for the treatment of children is contraindicated.
The ability to influence the speed of reaction when driving a vehicle or working with other mechanisms. If there is dizziness after the use of the drug No-Spa, you should refrain from driving the vehicle and performing work that requires increased attention.
Interactions:
PDE inhibitors (No-Shpa forte, papaverine) reduce the antiparkinsonian effect of levodopa. Care should be taken when using the drug with levodopa at the same time, since the antiparkinsonian effect of the latter decreases and an increase in tremor and rigidity is observed.
Overdose:
There is no evidence of an overdose of drotaverin. In case of overdose, the patient should be under the strict supervision of the doctor, symptomatic and supportive treatment is carried out. It is recommended to induce vomiting and/or rinse the stomach.
CHARACTERISTIC: in a place protected from light at a temperature of 15-25 ° C.
